Welcome to our dedicated page for Lexeo Therapeutics SEC filings (Ticker: LXEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lexeo Therapeutics, Inc. (LXEO) SEC filings page on Stock Titan aggregates the company’s public regulatory documents from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret key disclosures. As a Nasdaq-listed, clinical stage genetic medicine company, Lexeo uses filings such as Forms 8-K, 10-Q, and 10-K to report material events, financial results, and risk factors related to its gene therapy programs and corporate activities.
In its 8-K filings, Lexeo has reported items such as quarterly financial results, equity financings through underwritten public offerings and concurrent private placements, material definitive agreements like underwriting and securities purchase agreements, and registration rights agreements related to pre-funded warrants. The company also uses 8-Ks to furnish press releases that provide interim clinical and regulatory updates for its lead programs, LX2006 in Friedreich ataxia (FA) cardiomyopathy and LX2020 in PKP2-associated arrhythmogenic cardiomyopathy.
Filings also describe Lexeo’s interactions with the FDA, including feedback on potential accelerated approval pathways, participation of LX2006 in the Chemistry, Manufacturing, and Controls Development and Readiness Pilot program, and regulatory designations such as Breakthrough Therapy, RMAT, Orphan Drug, Rare Pediatric Disease, and Fast Track. Corporate governance matters, executive appointments, compensation arrangements, and stockholder meeting results are likewise documented in SEC reports.
On Stock Titan, investors can review these filings alongside AI-generated highlights that summarize complex sections, helping to identify information on clinical development plans, capital structure changes, and other material disclosures. Real-time updates from EDGAR, combined with structured access to forms such as 10-K annual reports, 10-Q quarterly reports, and 8-K current reports, support deeper analysis of Lexeo’s regulatory and financial reporting history.
Lexeo Therapeutics, Inc. Chief Executive Officer Richard Nolan reported an open-market sale of 55,000 shares of common stock at a weighted average price of $5.6934 per share. The sale on April 6, 2026 was made under a pre-arranged Rule 10b5-1 trading plan.
Following this transaction, Nolan directly holds 340,106 shares of Lexeo common stock, which includes 261,349 Restricted Stock Units that may convert into shares if vesting conditions are satisfied.
Lexeo Therapeutics files its annual report detailing a clinical-stage genetic medicine pipeline focused on cardiovascular and neurodegenerative diseases. The company is advancing AAVrh10-based gene therapies, led by LX2006 for Friedreich ataxia cardiomyopathy and LX2020 for PKP2‑arrhythmogenic cardiomyopathy.
Interim Phase 1/2 data for LX2006 show increased cardiac frataxin expression and meaningful improvements in cardiac structure, biomarkers and neurologic function, supported by multiple FDA designations and alignment on a registrational SUNRISE‑FA 2 study. LX2020 has demonstrated dose‑dependent PKP2 protein restoration and reduced arrhythmia burden in PKP2‑ACM patients. As of June 30, 2025, non‑affiliate equity market value was approximately $216.5 million, and 74,087,063 common shares were outstanding as of March 27, 2026.
Lexeo Therapeutics reported fourth quarter and full year 2025 results and detailed progress across its cardiac gene therapy pipeline. The company ended December 31, 2025 with cash, cash equivalents and investments of $246.6 million, which it believes will fund operations into 2028.
For 2025, research and development expenses were $63.8 million, down from $74.1 million in 2024, while general and administrative expenses rose to $45.5 million from $31.7 million, reflecting growth investments. Net loss for 2025 was $100.0 million, or $1.86 per share, broadly similar to 2024.
Operationally, Lexeo advanced lead programs LX2006 for Friedreich ataxia cardiomyopathy and LX2020 for PKP2 arrhythmogenic cardiomyopathy, including positive interim data, FDA alignment on the SUNRISE‑FA 2 pivotal trial design, and preparation for a Biologic License Application for LX2006. The company also highlighted a research collaboration with Johnson & Johnson on targeted cardiac delivery of AAV gene therapy and a previously executed $154 million equity financing to support its expanding cardiovascular pipeline.
Lexeo Therapeutics Inc ownership disclosure: The Vanguard Group filed an amended Schedule 13G/A reporting 0 shares beneficially owned and 0% of Lexeo Therapeutics common stock as of the filing. The amendment notes an internal realignment on January 12, 2026 and states certain Vanguard subsidiaries now report separately in reliance on SEC Release No. 34-39538.
Lexeo Therapeutics Chief Executive Officer Richard Nolan Townsend acquired 2,623 shares of common stock at $2.644 per share through the company’s 2023 Employee Stock Purchase Plan, in a transaction exempt under Rule 16b-3(c) and 16b-3(d). Following this award, he directly holds 395,106 shares, including 261,349 restricted stock units.
Lexeo Therapeutics, Inc. Chief Operating Officer Jose Manuel Otero acquired 5,930 shares of common stock on March 13, 2026 at $2.644 per share through the company’s 2023 Employee Stock Purchase Plan. After this transaction, he holds 131,390 shares in total, including 104,216 restricted stock units, in a transaction exempt under Rule 16b-3(c) and 16b-3(d).
Lexeo Therapeutics Chief Operating Officer Jose Manuel Otero reported an open-market sale of 3,016 shares of common stock on February 18, 2026 at a weighted average price of $6.3972 per share. The sale was made to cover tax obligations on the release of restricted stock units. After this transaction, Otero beneficially owned 125,460 shares, including 104,216 restricted stock units.
Lexeo Therapeutics, Inc. Chief Executive Officer Richard Nolan Townsend reported an open-market sale of 10,173 shares of common stock at a weighted average price of $6.382 per share. According to the footnotes, this sale was made to cover tax obligations on the release of restricted stock units. Following the transaction, he directly holds 392,483 shares, which include 261,349 restricted stock units.
Lexeo Therapeutics, Inc. Chief Operating Officer Jose Manuel Otero corrected a prior insider trade report and detailed a small tax-related sale of shares. An earlier Form 4 had mistakenly stated that a sale to cover tax obligations occurred on August 18, 2025. This amendment clarifies that the open-market sale of 721 shares of common stock actually took place on November 18, 2025 at a weighted average price of $9.27 per share, executed in multiple trades between $9.09 and $9.37. The sale was made solely to cover tax obligations from the release of restricted stock units. After this transaction, Otero directly owns 63,476 shares of Lexeo Therapeutics common stock, including 47,733 RSUs, so his overall stake in the company remains largely unchanged.